Quantcast

Latest Roche Stories

2010-11-23 15:56:00

PRINCETON, N.J., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2010. At fiscal year end Pharmasset held $127.1 million in cash and cash equivalents. Pipeline Update and 2010 highlights RG7128 Phase 2b PROPEL and JUMP-C trials...

2010-11-05 06:30:00

SAN DIEGO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the third quarter ended September 30, 2010. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO) "Halozyme...

2010-10-11 15:05:00

SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram...

2010-10-04 07:00:00

NUTLEY, N.J. and BASEL, Switzerland Oct. 4 /PRNewswire/ -- Roche announced today that Jacques Banchereau, Ph.D., has joined Roche as Senior Vice President and Head of the Inflammation and Virology Discovery and Translational Areas (DTAs). In this role, he will oversee research and early development up to late stage development in the field of Inflammation, including autoimmune and respiratory diseases such as rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD) as well...

2010-09-20 08:00:00

NUTLEY, N.J., Sept. 20 /PRNewswire/ -- In an effort to stimulate local business activity and encourage its employees to build a deeper connection with the communities in which they work, today, Roche, in partnership with the North Jersey Regional Chamber of Commerce/Clifton Economic Develop Assistance Commission (CEDAC) and the Nutley Chamber of Commerce (NCoC), is launching the "Roche Goes to Town" program in Nutley and Clifton, New Jersey. Roche has provided each of its full-time New...

2010-08-04 12:49:00

IPSWICH, Mass., Aug. 4 /PRNewswire/ -- New England Biolabs is pleased to announce that Canada's Michael Smith Genome Sciences Center has selected New England Biolabs as one of its key suppliers for next-generation sequencing library construction reagents. NEBNext DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited and validated for sample preparation for next generation sequencing, as well as the preparation of expression libraries. Reagents are available for...

2010-07-26 08:00:00

NUTLEY, N.J., July 26 /PRNewswire/ -- Roche announced today that Karen Lackey has been named Vice President and Head of Medicinal Chemistry, effective immediately. In her role at the company's Nutley facility, Karen will be responsible for small molecule drug discovery in oncology, virology and inflammation. She will also oversee the Nutley Discovery Chemistry Management Team and be a member of the Global Chemistry Leadership Team. Karen will report to Hans-Joachim Boehm, Ph.D., Global Head...

48a1727f8de003247378c30a59ea9b72
2010-07-17 06:40:57

Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed it failed to slow tumor growth or extend patient lives. The Food and Drug Administration approved Roche's blockbuster Avastin in 2008 based on early-stage trials after it was seen that it shrank tumors caused by breast cancer.  The decision was controversial because drugs for cancer patients who have never been treated before must show evidence that they extend lives. Avastin's so-called...

2010-07-13 13:12:00

IPSWICH, Mass., July 13 /PRNewswire/ -- New England Biolabs (NEB) has expanded its line of reagents for sample preparation with the introduction of NEBNext(TM) Quick DNA Sample Prep Reagent Set 2 and Master Mix Set 2, both suitable for library construction for Roche's 454 GS FLX Titanium(TM) and GS Junior(TM) instruments. These new products provide all the necessary enzymes and buffers for fast fragment library preparation. The Master Mix Set further streamlines the workflow, reducing the...

2010-07-01 09:00:00

WALTHAM, Mass., July 1 /PRNewswire/ -- X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets. As part of the agreement, Roche will provide X-Chem with upfront and research payments, success-based discovery milestones, and technology access fees. Roche will have the right to develop and commercialise any product...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related